Edwards Lifesciences Corporation $EW Stock: One Way Holdings LLC Lowers Position

One Way Holdings LLC reduced its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 5.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 251,883 shares of the medical research company’s stock after selling 14,489 shares during the quarter. One Way Holdings LLC’s holdings in Edwards Lifesciences were worth $21,743,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of EW. Flagship Harbor Advisors LLC lifted its stake in shares of Edwards Lifesciences by 1.2% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 10,615 shares of the medical research company’s stock valued at $916,000 after purchasing an additional 125 shares during the period. Fifth Third Wealth Advisors LLC boosted its position in Edwards Lifesciences by 1.8% during the third quarter. Fifth Third Wealth Advisors LLC now owns 7,268 shares of the medical research company’s stock worth $627,000 after purchasing an additional 132 shares in the last quarter. Signaturefd LLC increased its position in shares of Edwards Lifesciences by 1.4% in the third quarter. Signaturefd LLC now owns 10,034 shares of the medical research company’s stock valued at $866,000 after buying an additional 142 shares in the last quarter. NorthRock Partners LLC raised its stake in shares of Edwards Lifesciences by 1.0% during the 2nd quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock worth $1,465,000 after buying an additional 153 shares during the period. Finally, Soltis Investment Advisors LLC raised its stake in shares of Edwards Lifesciences by 2.4% during the 3rd quarter. Soltis Investment Advisors LLC now owns 6,479 shares of the medical research company’s stock worth $559,000 after buying an additional 153 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Annette Brüls sold 2,644 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 5,045 shares of company stock worth $451,596 over the last three months. Insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on EW. Sanford C. Bernstein boosted their price target on shares of Edwards Lifesciences from $96.00 to $99.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Truist Financial boosted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Citigroup restated a “buy” rating and set a $101.00 price target (up from $96.00) on shares of Edwards Lifesciences in a research report on Monday, October 5th. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $101.16.

Edwards Lifesciences Trading Down 0.1%

Shares of EW opened at $91.91 on Monday. Edwards Lifesciences Corporation has a 52-week low of $74.66 and a 52-week high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm’s fifty day moving average is $88.15 and its two-hundred day moving average is $85.43. The stock has a market cap of $52.92 billion, a PE ratio of 52.82, a price-to-earnings-growth ratio of 2.41 and a beta of 0.87.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.